{
    "organizations": [],
    "uuid": "8483e3c42f381cc2c7a9e0dcd52b76f68e2895df",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-clearside-biomedical-announces-res/brief-clearside-biomedical-announces-results-from-phase-3-trial-of-cls-ta-idUSASB0C8PV",
    "ord_in_thread": 0,
    "title": "BRIEF-Clearside Biomedical Announces Results From Phase 3 Trial Of CLS-TA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Clearside Biomedical Inc:\n* CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF CLS-TA IN MACULAR EDEMA ASSOCIATED WITH NON-INFECTIOUS UVEITIS\n* PRIMARY ENDPOINT ACHIEVED IN PHASE 3 CLINICAL TRIAL OF CLS-TA\n* ALL KEY SECONDARY ENDPOINTS ACHIEVED IN STUDY * STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROPORTION OF PATIENTS GAINING 15 OR MORE LETTERS IN VISUAL ACUITY IN STUDY\n* SUPRACHOROIDAL CLS-TA WAS GENERALLY WELL TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED IN TRIAL\n* EXPECT TO SUBMIT NDA FOR SUPRACHOROIDAL CLS-TA IN PATIENTS WITH MACULAR EDEMA ASSOCIATED WITH UVEITIS TO FDA IN Q4 2018\n* EVALUATING OPTIONS FOR SUBMISSIONS TO REGULATORY AGENCIES IN TERRITORIES OUTSIDE OF U.S. FOR SUPRACHOROIDAL CLS-TA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-05T20:16:00.000+02:00",
    "crawled": "2018-03-06T22:31:45.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "clearside",
        "biomedical",
        "inc",
        "clearside",
        "biomedical",
        "announces",
        "positive",
        "topline",
        "result",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "macular",
        "edema",
        "associated",
        "uveitis",
        "primary",
        "endpoint",
        "achieved",
        "phase",
        "clinical",
        "trial",
        "key",
        "secondary",
        "endpoint",
        "achieved",
        "study",
        "statistically",
        "significant",
        "improvement",
        "proportion",
        "patient",
        "gaining",
        "letter",
        "visual",
        "acuity",
        "study",
        "suprachoroidal",
        "generally",
        "well",
        "tolerated",
        "serious",
        "adverse",
        "event",
        "reported",
        "trial",
        "expect",
        "submit",
        "nda",
        "suprachoroidal",
        "patient",
        "macular",
        "edema",
        "associated",
        "uveitis",
        "fda",
        "q4",
        "evaluating",
        "option",
        "submission",
        "regulatory",
        "agency",
        "territory",
        "outside",
        "suprachoroidal",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}